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The Netherlands and 5) Department of Life Sciences, Natural History Museum, London, UKAbstractSchistosomiasis is a water-based parasitic disease that affects over 250 million people. Control efforts have long been in vain, which is one
reason why schistosomiasis is considered a neglected tropical disease. However, since the new millennium, interventions against
schistosomiasis are escalating. The initial impetus stems from a 2001 World Health Assembly resolution, urging member states to scale-
up deworming of school-aged children with the anthelminthic drug praziquantel. Because praziquantel is safe, efﬁcacious and inexpensive
when delivered through the school platform, diagnosis before drug intervention was deemed unnecessary and not cost-effective. Hence,
there was little interest in research and development of novel diagnostic tools. With the recent publication of the World Health
Organization (WHO) Roadmap to overcome the impact of neglected tropical diseases in 2020, we have entered a new era. Elimination
of schistosomiasis has become the buzzword and this has important ramiﬁcations for diagnostic tools. Indeed, measuring progress
towards the WHO Roadmap and whether local elimination has been achieved requires highly accurate diagnostic assays. Here, we
introduce target product proﬁles for diagnostic tools that are required for different stages of a schistosomiasis control programme. We
provide an update of the latest developments in schistosomiasis diagnosis, including microscopic techniques, rapid diagnostic tests for
antigen detection, polymerase chain reaction (PCR) assays and proxy markers for morbidity assessments. Particular emphasis is placed on
challenges and solutions for new technologies to enter clinical practice.
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E-mail: juerg.utzinger@unibas.chIntroductionFrom a global public health perspective, schistosomiasis is the
most important water-based disease [1]. Schistosomiasis is a
neglected tropical disease (NTD) that is caused by chronic
infection with blood ﬂukes of the genus Schistosoma. Three
species are of particular relevance; Schistosoma haematobium,
which occurs in Africa and the Arabian Peninsula, SchistosomaClinical Microbiology and Infection © 2015 European Society of Cmansoni, which is endemic in Africa, the Arabian Peninsula,
South America and the Caribbean, and Schistosoma japonicum,
which is restricted to China, the Philippines and Indonesia [2,3].
Humans become infected when they contact freshwater bodies
infested with schistosome cercariae that are released from in-
termediate host snails [3]. Schistosomiasis is a disease of
poverty and is associated with a lack of clean water at home,
which forces people to contact unprotected natural open
freshwater sources where transmission occurs [4–6].
The symptomatology and severity of disease depend on the
schistosome species, the total number of blood ﬂukes har-
boured in a host, length of infection, level of host immunity, age
and gender [3,7]. Almost 800 million people were at risk of
schistosomiasis in mid-2003 [1]. Estimates for 2010 suggest that
over 250 million people were infected and the disease causedClin Microbiol Infect 2015; 21: 529–542
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adjusted life years [8,9]. Water resources development and
management (e.g. large dams and irrigation systems) are key risk
factors for the spread and intensiﬁcation of schistosomiasis [1].
Climate change is likely to exacerbate transmission or extend
the disease further north or into higher altitudes [10–15]. High
mobility of people and migration bear the risk of (re-)intro-
ducing schistosomiasis transmission into areas that had been
considered to be non-endemic or that managed to locally
eliminate the disease, despite the presence of intermediate host
snails [16]. A recent example is infection of people with
S. haematobium after bathing in the Cavu River in southern
Corsica. The life cycle might have been initiated by an infected
individual excreting S. haematobium eggs into the river and the
presence of suitable intermediate host snails (i.e. Bulinus trun-
catus) [17,18]. Hence, there is a risk of acquiring schistosomiasis
among travellers and expatriates from non-endemic areas who
might occasionally contact contaminated freshwater through
leisure bathing or water sport activities [19].
Although travellers and tourists are usually diagnosed with
schistosomiasis only upon return to their home country and
are managed according to speciﬁc guidelines there, the control
of schistosomiasis in countries where schistosomiasis is
endemic emphasises large-scale administration of praziquantel
without prior diagnosis; a strategy phrased ‘preventive
chemotherapy’ (PCT) [20]. Countries that have effectively
reduced morbidity due to schistosomiasis are encouraged to
move towards elimination of this infection as a public health
problem by reducing heavy infection intensities in at-risk pop-
ulations to below 1% [21]. For this purpose, it is recommended
that PCT should be combined with other interventions, such as
improved access to clean water, sanitation and hygiene
(WASH), information, education and communication (IEC) and
snail control [22]. Interventions should go hand-in-hand with
effective surveillance–response mechanisms, readily tailored to
social–ecological systems [21,23,24].
For individual patient management of returning travellers and
for different stages of a schistosomiasis control programme,
appropriate diagnostic tools are required, as speciﬁed in target
product proﬁles [25–29]. Tools for the rapid identiﬁcation of
high-risk communities at the onset of a control programme
(e.g. simple school-based questionnaires) and for an assessment
of prevalence and intensity of infection in morbidity control
settings (e.g. microscopy) are readily available and recom-
mended by the World Health Organization (WHO) [30].
However, diagnostic assays that are highly sensitive and speciﬁc,
and hence appropriate for monitoring and surveillance, post-
transmission control and veriﬁcation of elimination have yet
to be standardised and recommended for wider use. Here, we
review and discuss widely employed tests and new promisingClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectassays to diagnose schistosomiasis. Particular emphasis is placed
on the challenges for new technologies to enter clinical
practice.Diagnostic toolsFor decades, innovation, research and development of drugs
and vaccines for schistosomiasis and other NTDs have been
neglected. For instance, an analysis of 1393 new chemical en-
tities that were brought to market between 1975 and 1999
revealed that only 16 (1.1%) were for NTDs and tuberculosis
[31]. In a more recent systematic assessment covering the
period 2000–2011, it was found that among 850 new thera-
peutic entities, 37 (4.4%) had an indication for NTDs. However,
most of them pertained to existing products that have been
repurposed [32]. With regard to diagnostics for NTDs, the
situation might be even worse. Indeed, innovation has often
been stalled because of a general belief that the control and
elimination of schistosomiasis and other NTDs could be ach-
ieved with the available tools [33].
At the 54th World Health Assembly in May 2001, PCT was
endorsed as the global control strategy against schistosomiasis
(and soil-transmitted helminthiasis) [34]. Subsequently, WHO
presented a vision with a progressive shift from morbidity
control to interruption of transmission and ﬁnally elimination
[35]. However, little attention was paid to the role of di-
agnostics. This issue had been emphasised in 2009, along with
an attempt to highlight different diagnostic tools that can be
used for different stages of a schistosomiasis control pro-
gramme [25]. In 2012, the ﬁght against NTDs was reinforced by
the London Declaration and the WHO Roadmap for NTDs. As
a consequence, the elimination of schistosomiasis transmission
became the declared objective [16,36,37] and the need to
develop and apply new, highly sensitive and speciﬁc diagnostic
tools that are adapted to low-transmission settings was stressed
[21,27].
Target product proﬁles, standard protocols and
preferred reporting
Recognising the pivotal role of diagnostics, there is a need for
target product proﬁles that are readily adapted to speciﬁc stages
of a control programme [26]. Table 1 summarises two target
product proﬁles for diagnostic tools for schistosomiasis at two
distinct stages of control: (a) at an early stage when the focus is
on mapping (establishing baseline disease prevalence and facili-
tating spatial targeting of interventions) and impact monitoring
(determining prevalence after interventions have commenced);
and (b) at a late stage during the post-elimination surveillance
(rigorous surveillance after interventions have ceased).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
TABLE 1. Key characteristics of target product proﬁles for diagnostic tools that are readily adapted to two speciﬁc stages of a
schistosomiasis control programmea
Characteristic
Onset of a control programme
(mapping and impact monitoring)
Late-stage of a control programme
(post-elimination surveillance)
Possible target population School-aged children Children who are born after transmission has been interrupted
Possible sample type Questionnaire, urine or blood spot (if possible, avoid stool) Urine or blood spot (if possible, avoid stool)
Ideal diagnostic marker Species-speciﬁc antigen Species-speciﬁc antigen or antibody
Ideal test format Point-of-care rapid diagnostic test High-throughput laboratory assay
Required performance characteristics Sensitivity: >50% Sensitivity: >99%
Speciﬁcity: >95% Speciﬁcity: >99%
Current reference standard Kato–Katz thick smear (Schistosoma mansoni and
Schistosoma japonicum)
Kato–Katz thick smear (S. mansoni and S. japonicum)
Urine ﬁltration (Schistosoma haematobium) Urine ﬁltration (S. haematobium)
aTable adapted from Solomon et al. [26].
CMI Utzinger et al. New diagnostics for schistosomiasis 531In recent years, efforts have been made to standardise diag-
nostic protocols and to improve the accuracy and completeness
of reporting on diagnostic studies. Of particular note is the
STARD initiative (‘STAndards for the Reporting of Diagnostic
accuracy studies’) that came forward with a 25-item checklist
that should be included for reporting diagnostic accuracy studies.
The use of a ﬂow diagram detailing the design of the study,
methods for recruitment, order of test execution, ﬂow of par-
ticipants and presentation of decisive and indecisive test results is
strongly encouraged [38,39]. Moreover, the validation of existing
and new tools for schistosomiasis diagnosis is making progress
[40–42], most prominently in multi-country studies [43].
Table 2 summarises a host of methods that are being used
for schistosomiasis diagnosis. The tests are listed in the order in
which they might be most useful at speciﬁc stages of a control
programme; from rapid screening of high-risk communities
using simple school-based questionnaires to molecular ap-
proaches in reference laboratories that might be necessary for
post-transmission surveillance.
Tests for rapid assessment, mapping and monitoring
Chronic infection with S. haematobium can cause inﬂammation of
the urogenital tract, resulting in ulceration and bleeding into urine
[44]. Populations characterised by high S. haematobium infection
levels can be identiﬁed rapidly and at low cost, using simple school-
based questionnaires that assess for self-reported blood in urine
[45–47]. Visible haematuria declines after antischistosomal
treatment, and hence, self-reported haematuria has only limited
diagnostic value as schistosomiasis control progresses [48].
Reagent strips for detecting microhaematuria in urine, in
contrast, are useful tools for the indirect diagnosis of
S. haematobium infection also in low-prevalence settings and in
populations subjected to PCT [44,48,49]. Reagent strips are
therefore suggested as appropriate adjuncts for monitoring
urogenital schistosomiasis control programmes [44,48].
For the rapid identiﬁcation of communities at high risk of
intestinal schistosomiasis, questionnaires assessing blood in theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologystool showed a lower accuracy than self-reported blood in
urine for community diagnosis of S. haematobium [46]. A
commercially available lateral ﬂow immune-chromatographic
reagent strip test detecting circulating cathodic antigen (CCA)
in urine has been applied in the past as an early indicator of
S. mansoni infections, particularly in young children, who have
yet to become egg- or antibody-patent [50]. Since 2008, a more
sophisticated point-of-care (POC) test detecting Schistosoma
CCA in urine has been developed and is now commercially
available and recommended by the authors for S. mansoni
prevalence mapping. Indeed, this POC-CCA urine cassette test
has been shown to accurately detect S. mansoni infections in
different age groups, countries and evaluations [43,51–55]. The
test is also able to diagnose the two Asian schistosome species;
S. japonicum and Schistosoma mekongi [41,56]. The evidence
accrued so far suggests that a single POC-CCA cassette test is
considerably more sensitive than conventional stool micro-
scopy using Kato–Katz thick smear for S. mansoni diagnosis,
particularly when infection intensities are low and after
anthelminthic treatment [50,54,57,58]. Hence, the POC-CCA
cassette test is suggested as an appropriate tool for moni-
toring schistosomiasis control programmes that progress from
morbidity control towards elimination [57,58].
Urine and stool microscopy
S. haematobium eggs excreted in urine can be trapped on poly-
carbonate ﬁlters with a ﬁne pore size of 8–30μmafter 10mL of a
well shaken mid-day urine sample is passed through a syringe
[59]. Eggs on the ﬁlter are usually stained with Lugol’s iodine and
counted under a microscope. Infection intensity is expressed as
the number of eggs per 10mL of urine with a threshold of 50 eggs
distinguishing between light and heavy infection [34]. Although
this method is easy to perform, it lacks sensitivity to detect very
light infection intensities and is affected by day-to-day variation in
egg output [60–62]. Hence, to accurately detect light infections,
multiple ﬁltrations over consecutive days are needed. In a recent
proof-of-concept study, urine sample preparations in the ﬁeldand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
TABLE 2. Accuracy and applicability of different tests for the diagnosis of Schistosoma infections in humans
Method Unit of diagnosis Sensitivity Speciﬁcity Quantiﬁcation High throughput PHCU Laboratory Reference laboratory Commercially available Cost Reference(s)
Colour of urine
Questionnaire Red urine x x x xxx xxx xxx xxx N/A x [46]
Visible haematuria Macrohaematuria x x x xxx xxx xxx xxx N/A x [46]
Rapid tests
Reagent strip Microhaematuria x x xx xxx xxx xxx xxx xxx xx [44]
POC-CCA Circulating cathodic antigen xxx xxx xx xxx xxx xxx xxx xxx xx [43]
Microscopy
Urine ﬁltration S. haematobium eggs xx xxx xxx xx N/A xxx xxx N/A xx [59]
Direct faecal smear S. mansoni eggs,
S. japonicum eggs
x xxx x xx N/A xxx xxx N/A xx [64,65]
FECT S. mansoni eggs,
S. japonicum eggs
x xxx x xx N/A xxx xxx N/A xx [65,67]
Kato-Katz S. mansoni eggs,
S. japonicum eggs
xx xxx xxx xx N/A xxx xxx xx xx [30,68,69]
FLOTAC S. mansoni eggs,
S. japonicum eggs
xx xxx xxx x N/A xxx xxx N/A xx [76]
Mini-FLOTAC S. mansoni eggs,
S. japonicum eggs
xx xxx xxx xx N/A xxx xxx N/A xx [77]
Antibody detection
ELISA Anti-Schistosoma antibody xxx x x xxx N/A x xx N/A xxx [61]
IHA Anti-Schistosoma antibody xxx x x xxx N/A x xx N/A xxx [61]
Antigen detection
UCP-LF CAA Circulating anodic antigen xxx xxx xx xx N/A x xxx N/A xxx [92]
DNA detection
PCR Schistosoma DNA xxx xxx xx xx N/A x xx N/A xxx [95]
LAMP Schistosoma DNA xxx xxx xx xx N/A x xxx N/A xxx [95]
The following grading system was used: x, low; xx, moderate; xxx, high; N/A, not applicable/not available.
ELISA, enzyme-linked immunosorbent assay; FECT, formalin–ether concentration technique; IHA, indirect haemagglutination assay; LAMP, loop-mediated isothermal ampliﬁcation; PCR, polymerase chain reaction; PHCU, primary healthcare unit
(without microscope, centrifuge and other technical equipment); POC-CCA, point-of-care circulating cathodic antigen; UCP-LF CAA, up-converting phosphor-lateral ﬂow circulating anodic antigen (urine-based).
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CMI Utzinger et al. New diagnostics for schistosomiasis 533were carried out successfully using readily available paper
products (e.g. newspaper, school workbook paper and single-ply
paper towels) to gravity-ﬁlter urine [63].
The direct faecal smear (also known as wet-mount prepa-
ration) is routinely used in many laboratories for the detection
of intestinal protozoa and helminth infections. Its preparation is
straightforward. In brief, approximately 2 mg of fresh stool are
added to a drop of saline (or iodine for intestinal protozoa),
mixed and directly examined under a microscope [64,65].
Although the simplicity and concurrent detection of multiple
parasite species is an advantage and the method has a reason-
able sensitivity to detect intestinal protozoa infections, it shows
low sensitivity for helminth infections, including S. mansoni [66].
The formalin-ether concentration technique (FECT) is often
used in combination with the direct faecal smear in hospital
laboratories in high-income countries. In brief, the procedure
includes four steps: (a) homogenisation of approximately
1.0–1.5 g of stool in formalin; (b) ﬁltration of the stool–
formalin suspension through a 400-μm sieve or surgical gauze;
(c) addition of ether and centrifugation of the stool–
formalin–ether mix; and (d) microscopic examination of the
sediment layer [65,67]. Although more sensitive than a direct
faecal smear, FECT is characterised by low sensitivity for
detecting S. mansoni infections [40,66].
The Kato–Katz technique is the standard method to assess
the prevalence and intensity of infection with S. mansoni (as well
as S. japonicum and soil-transmitted helminths) in endemic
countries [30,68,69]. In brief, fresh stool is pressed through a
ﬁne 60- to 105-μm mesh and ﬁlled in a plastic or stainless steel
template designed to transfer 41.7 mg or 25 mg of stool,
respectively, on a microscope slide. The resulting small stool
cylinder on the slide is covered with glycerol–methylene blue-
soaked cellophane, evenly spread and examined under a mi-
croscope. After a clearing time of at least 30 min, but ideally
about 24 hours, the number of S. mansoni (or S. japonicum) eggs
in the thick smear can be counted under a microscope and is
expressed as the number of eggs per gram of stool (EPG) after
multiplication with the appropriate factor (24 or 40, depending
on the amount of stool). Of note, Kato–Katz thick smears are
usually examined for concurrent soil-transmitted helminth eggs.
The EPG values are used as a proxy for infection intensity. The
Kato–Katz technique is relatively simple and inexpensive and
sufﬁciently sensitive to detect moderate and heavy S. mansoni
infections [28]. However, its ability to detect light infections is
compromised by its relatively low detection limit (around
20–50 EPG, depending on the templates used). Hence, it might
(a) underestimate the true prevalence, particularly in low-
prevalence settings; and (b) confound conﬁrmation of cure
after treatment [28,57,70]. A latent Markov modelling approach
conﬁrmed that the sensitivity of the Kato–Katz method isClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologysigniﬁcantly lower in the weeks post-treatment with prazi-
quantel compared with pre-treatment assessment [71], which is
probably due to a reduced worm load, and hence a low egg
output after treatment. A commercially available portable light
microscope (Newton Nm1-600 XY) showed good diagnostic
accuracy for S. mansoni detection using Kato–Katz thick
smears, whereas a novel mobile phone microscope only
resulted in moderate sensitivity [72].
FLOTAC is a technique that has been developed by a vet-
erinary parasitologist for the diagnosis of intestinal parasites in
different domestic animal species [73]. Subsequently, FLOTAC
has been broadly validated for the diagnosis of human nematodes
and trematodes, including S. mansoni [40,74–76]. Mini-FLOTAC
is a further development of the initial FLOTAC technique
[66,77,78]. Of note, the principle of the FLOTAC family is ho-
mogenisation of approximately 1 g of stool in formalin, ﬁltration
to remove debris, and addition of a ﬂotation solution with a
speciﬁc gravity to bring helminth eggs into ﬂotation. There are
speciﬁcally designed FLOTAC devices that enable the ﬂotation of
eggs, translation and subsequent visualisation under a
microscope. Although the original FLOTAC technique bears the
advantage that the complete 1 g of stool can be examined, it
requires a large-bucket centrifuge that might not be available in
resource-constrained settings. The Mini-FLOTAC is designed to
overcome the restriction of centrifugation and still has a
detection limit of 10 EPG [66]. First applications in the ﬁeld
showed that it detects S. mansoni infections with a higher
accuracy than the direct faecal smear, FECT and Kato–Katz
thick smear [66,79].
Serological tests
Serological detection of anti-schistosome antibodies in human
blood is commonly employed to determine whether or not an
individual has been previously exposed to schistosomes. In
most cases, antibodies develop within 6–8 weeks after infection
and are frequently detectable before Schistosoma eggs can be
found microscopically in stool or urine samples. However, very
early infections may still be missed [7]. At a later stage of
infection, antibody detection has a good sensitivity, but is only
moderately speciﬁc and cannot distinguish between the
different Schistosoma species [80]. Positive results indicate
active or past infection, but fail to readily distinguish between
both conditions, because high antibody titres may persist for
long periods after schistosomiasis has been successfully treated
and cured. Hence, antibody detection is of low diagnostic value
for the detection of active infection in highly endemic areas
where exposure to schistosomes is common. One exception is
the application of serology to detect initial active infection in
young children who are not yet egg-patent but might require
special care [50,81].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
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mission is assumed, serology plays an important role as a
conﬁrmatory diagnostic tool to prove that people living in
formerly endemic areas are indeed no longer exposed to the
infective agent [28]. Moreover, serological tests are a powerful
tool for the detection of schistosomiasis in travellers returning
from endemic settings (e.g. in Western travel clinics). Indeed,
signs and symptoms in individuals with light-intensity infections
are unspeciﬁc and often absent, so that clinical examination and
egg microscopy alone do not reach satisfactory sensitivity.
Recent investigations built around the acquisition of
S. haematobium infections in individuals during travel to Corsica
conﬁrmed this observation: serology identiﬁed several in-
fections that were missed by urine microscopy [17]. In clinical
practice, a positive serology in people from non-endemic
countries who have been exposed to freshwater in
schistosomiasis-endemic areas is usually sufﬁcient to prescribe
treatment with praziquantel [82,83].
Different test methodologies have been developed for the
serodiagnosis of schistosomiasis, among which enzyme-linked
immunosorbent assay (ELISA) techniques using soluble
S. mansoni egg antigens and indirect haemagglutination assays
(IHAs) with adult S. mansoni worm antigen are commonly used
[84]. However, although there are a couple of commercially
available antibody detection assays, they are not standardised
among the companies and users. Most laboratories employ their
own assays and/or have their ﬁxed suppliers. Combining assays
with different antibody-isotype or antigen combinationsmay lead
to an improved diagnostic accuracy. Cross-reactions between
antibodies directed against schistosomes and other trematodes
are frequent, which is why some guidelines recommend per-
forming concurrent serological testing for Fasciola spp. in case of
positive schistosome serology [85].
Although the available serodiagnostic tools use antigen
originating from S. mansoni, also infections due to the other
Schistosoma spp. are detected with high sensitivity [86].
Obtaining S. mansoni worm and egg antigens from infected
animals is a mandatory prerequisite for the development of the
most commonly employed serodiagnostic tools. However, this
process is rather laborious, expensive and may limit the suit-
ability of these serological tests for use in resource-constrained
settings. More recently, efforts have been made to develop
antibody detection assays that use S. mansoni cercarial anti-
gens—commonly referred to as S. mansoni cercarial trans-
formation ﬂuid—which are easier to produce because they can
be obtained from infected intermediate host snails. The diag-
nostic performance is comparable to that of routinely
employed serological tests [87]. Indeed, a rapid diagnostic test
(RDT) format using S. mansoni cercarial transformation ﬂuid
antigen has been developed and validated in different settings,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectreporting high sensitivity, which calls for further investigation
[80,88,89].
New diagnostic tools
Antigen detection tests. Novel tools showing a very high diag-
nostic accuracy, namely monoclonal antibody-based antigen
detection techniques, have recently been developed [90,91].
These assays, using an up-converting phosphor-lateral ﬂow
(UCP-LF) reporter technology, detect parasite-excreted
circulating anodic antigen (CAA) and CCA in serum or urine
at very low levels, which are indicative of single worm infections
[92]. Using urine as a non-invasive sample methodology, the
UCP-LF CAA assay has recently been used to evaluate
advanced schistosomiasis japonica screening and control pro-
grammes in China, showing evidence that triplicate Kato–Katz
thick smears might underestimate the prevalence of active
S. japonicum infections by a factor of 10 compared with the
UCP-LF CAA assay [41]. Applying the UCP-LF CAA test for
S. haematobium diagnosis in a close-to-elimination setting in
Zanzibar, United Republic of Tanzania, showed that the
empirical prevalence revealed with the UCP-LF CAA was
several-fold higher than the prevalence detected with a single
urine ﬁltration [42]. Noteworthy, the IHAs applied as the ﬁrst-
line screening tool in China fell short in about 50% of active
cases. The speciﬁcity of the UCP-LF CAA assay is warranted by
the complete uniqueness of the antigen, by highly speciﬁc
monoclonal antibody detection, as well as enrichment of the
CAA following sample pretreatment by trichloroacetic acid.
Experimental infections of mice, rabbits and baboons with
Schistosoma and post-treatment studies in humans indicate the
correlation of serum CAA levels with the number of living adult
worms [93,94]. The UCP-LF CAA assay was recently adapted
to a dry reagent format that allows convenient storage at
ambient temperature and worldwide shipping without the need
for a cold chain [91]. The possibility of concentrating larger
urine volumes allows the approach using pooled samples for a
more cost-effective way of screening speciﬁc population groups
in close-to-elimination settings [92].
DNA detection tests. For the detection and quantiﬁcation of
Schistosoma-speciﬁc DNA in clinical samples, a number of mo-
lecular techniques and a range of DNA targets have been
described, elegantly summarised in a recent review [95]. All
studies claim a speciﬁcity of virtually 100%, but sensitivities
range from equal to, up to substantially higher than traditional
microscopy techniques. This range largely reﬂects the quality
and quantity of the microscopy procedures used in the different
studies [96–98]. For the detection of DNA in urine, the
sensitivity further increases by the use of concentration pro-
cedures such as sedimentation or ﬁltration, the latter withious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
CMI Utzinger et al. New diagnostics for schistosomiasis 535potential application for population-based surveillance in more
remote endemic regions [99,100].
An advantage of using molecular diagnosis is the option to
detect Schistosoma DNA in alternative samples besides faeces
and urine, including semen and vaginal lavages, which may
facilitate the diagnosis of genital schistosomiasis [101]. More-
over, polymerase chain reaction (PCR) on gynaecological
samples seems to be a powerful diagnostic research tool in
further exploring the increased susceptibility of Schistosoma-
infected women to acquiring an human immunodeﬁciency virus
infection [102].
In endemic settings, PCR techniques can also be used to type
strains, which allows for the detection of hybrids between
human and animal schistosomes. Indeed, recent studies have
shown that natural interaction between S. haematobium and
Schistosoma bovis (a bovine Schistosoma species) does occur
[103]. Zoonotic hybrid schistosomes may develop when
humans and livestock are in contact with the same water
bodies, and such hybridisation may profoundly alter the para-
site’s biological characteristics, its transmission patterns, the
clinical course of infection and the sensitivity to anti-
schistosomal drugs [81,104]. New research is needed using
these molecular strain typing methods, as the results may
directly impact on current schistosomiasis control efforts.
For the diagnosis of early-stage infections, in particular in
travellers, there is a need for ultra-sensitive blood-based diag-
nostic tests, which can detect Schistosoma infection even before
serology and microscopy become positive. Detectable plasma
and serum levels of Schistosoma DNA have been reported
during acute human infection [105,106]. However, following
the administration of praziquantel, patients stayed positive for
many months [105–107]. It needs to be elucidated whether this
ﬁnding reﬂects continuous release of parasite DNA from tissue-
trapped eggs.
Despite the fact that PCR-based technology is highly speciﬁc
and sensitive, and despite its potential for high throughput
analysis (e.g. for population-based screening), DNA detection
tests are hardly used for clinical diagnosis within Schistosoma-
endemic countries because they require expensive laboratory
equipment and highly skilled personnel [108]. An interesting
alternative could be the use of loop-mediated isothermal
ampliﬁcation (LAMP) technology, which can be relatively easily
adapted to a basic laboratory under resource constraints. So
far, LAMP assays have been mainly used to study Schistosoma
infection in animal models or for the monitoring of Schistosoma-
infected snails [109].
Tests for morbidity assessment
While chronic inﬂammation of the affected organs occurs in any
type of schistosomiasis, symptoms are often unspeciﬁc andClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyassociated morbidity may not easily come to clinical attention.
Hence, in addition to the parasitological diagnosis of a Schisto-
soma infection, there is a need for comprehensive clinical as-
sessments to identify even subtle signs of disease. Although
quantiﬁcation of haematuria reliably indicates morbidity due to
urogenital schistosomiasis, the identiﬁcation of simple, ﬁeld-
applicable proxy markers for intestinal schistosomiasis is
more challenging. Recently, two faecal POC assays have been
shown to be strongly associated with heavy S. mansoni infection,
namely (a) faecal occult blood tests and (b) faecal calprotectin (a
calcium-binding protein of human neutrophils) [110]. It follows
that these markers may be used to reveal bowel morbidity
caused by intestinal schistosomiasis.
In clinical settings, ultrasound imaging of affected organs
(S. haematobium: urinary tract; S. mansoni: liver and spleen) is a
well established, widely accepted and accurate parameter to
assess morbidity due to chronic Schistosoma infection [111].Challenges for new technologies to enter
clinical practiceDiagnostic tests are central for adequate clinical patient man-
agement of Schistosoma-infected individuals and for successful
control programmes aiming at schistosomiasis elimination.
Despite the signiﬁcant progress made in the ﬁeld of diagnostic
test development, several barriers and obstacles exist that may
delay the widespread use of new diagnostic assays in clinical
practice.
Potential of new diagnostic technologies to enter
clinical practice
In Western travel clinics and hospital settings where schisto-
somiasis is encountered as an imported disease and infections
are usually of light intensity, early diagnosis and excellent
diagnostic accuracy are important test priorities. PCR tech-
niques provide a very high sensitivity and a rapid turn-around
time, but are technically demanding, require laboratories
equipped for molecular examinations, well-trained laboratory
technicians and are rather expensive so that these assays will
likely be limited to specialised laboratories. However, PCR
examinations for Schistosoma detection are increasingly avail-
able in national reference laboratories, allowing their use not
only for research purposes, but also in clinical practice as a
diagnostic tool to guide individual patient management. In
standard microbiology laboratories, however, microscopy using
a concentration technique currently remains the cornerstone
to prove active schistosomiasis. Given the low sensitivity of
microscopy for egg detection and the widely declining expertise
regarding microscopic parasite recognition outside endemicand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
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for S. mansoni holds promise to improve detection rates for
schistosomiasis with minimal turn-around times. Such RDTs
have been previously developed for detection of Giardia intes-
tinalis and Cryptosporidium spp. and have now become integral
parts of diagnostic testing algorithms in many clinical labora-
tories [112].
In resource-constrained settings where the highest disease
burden is concentrated, most patients present to district
hospitals or rural health dispensaries where no or only limited
diagnostic laboratory infrastructure is available. In these set-
tings, referral to better equipped institutions is the exception.
The availability of RDTs, which require only minimal infra-
structure, such as POC-CCA urine cassette test for the
detection of intestinal schistosomiasis, would much improve
diagnosis and at the same time surveillance in peripheral set-
tings [28]. If stool/urine microscopy is feasible in local labo-
ratories in endemic areas, direct faecal smears and Kato–Katz
thick smears may be combined with concentration methods
such as FECT or Mini-FLOTAC for an improved diagnosis of
schistosomiasis and potential parasitic co-infections. The Mini-
FLOTAC is particularly promising because its technical pro-
cedure does not require constant power supply. Both UCP-LF
CAA and PCR are highly sensitive, and allow for relatively high
throughput of samples. One trained technician can manage
several dozen UCP-LF CAA or PCR assays per day, provided
there are sufﬁcient centrifugation capacities, and a UCP-Quant
reader and a PCR thermal cycler, respectively, are available.
Such a throughput capacity would allow the use in large
screening programmes for near-elimination surveillance, as
well as the use as reference assays if modestly equipped cen-
tralised laboratories are available [108,113].
Current obstacles to successful implementation of new
diagnostics
The development of new diagnostic tests for schistosomiasis
has experienced similar challenges and barriers as previously
described for other NTDs, e.g. lack of funding and limited
commercial interest by private companies to invest in devel-
opment of tests that mainly target poor populations in low-
income countries [114]. Moreover, as long as morbidity con-
trol by PCT is the declared objective, diagnostics will remain
neglected because, economically, the costs of testing will
outweigh the costs of treatment. However, the drive towards
schistosomiasis elimination calls for developing novel diagnostic
tools with a high sensitivity and high speciﬁcity [16,21]. Reliably
identifying individuals with light-intensity infections that might
still contribute to the maintenance of transmission will be
crucial to achieve elimination. A test-and-treat strategy in close-
to-elimination settings or for post-elimination surveillanceClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmight be more cost-effective, less drug- and resource-wasting,
and ethically more appropriate than the large-scale distribu-
tion of drugs to mostly uninfected people.
Although considerable funding to develop and standardise
highly sensitive and speciﬁc diagnostic techniques is still needed,
signiﬁcant investments by the public sector and innovative
product development partnerships have been established over
the past years [115]. The POC-CCA for diagnosing schistoso-
miasis is a sensitive assay that is now commercially available and
can also be deployed in endemic areas without any laboratory
infrastructure. This RDT fulﬁls several of the ‘ASSURED
criteria’ that were elaborated to describe the characteristics of
an ideal diagnostic test in resource-constrained settings [114].
The acronym ASSURED speciﬁes the following requirements
that should be met by a test: A = affordable by the affected
individuals; S = sensitive; S = speciﬁc; U = user-friendly;
R = rapid turn-around time and robust performance (e.g. re-
agents tolerate tropical climate); E = equipment-free; and
D = delivered to those in need. While the POC-CCA test
meets most of these criteria, the current price (US$ 1.00–1.66
per test, depending on amount ordered) may prevent its use in
endemic settings, particularly in peripheral healthcare centres
where the test would be of greatest value.
In high-income countries where the individual test cost would
be of lesser importance, high investments are still required to
obtain ofﬁcial approval by the competent regulatory authorities,
namely the Medical Device Safety Service in the European Union
and the Food and Drug Administration in the USA [116]. Test
implementation at a larger scale is less likely to occur without
such approval. In addition, there is currently only one single
company from which the POC-CCA is commercially available
(Rapid Medical Diagnostics; Cape Town, South Africa).
Standardisation and appropriate handling of available tests
are crucial to obtain accurate, reliable test results. Indeed, the
diagnostic performance of malaria RDTs under operational ﬁeld
conditions has often been reported to be much lower than
initially expected [117], which underscores the need for
adequate training of the handling personnel. While this obser-
vation is true for all test formats, it is of particular relevance for
PCR-based diagnostics that are technically demanding and
should only be employed by well-trained personnel, including
rigorous quality control in each PCR run. To date, PCR diag-
nosis of schistosomiasis is based on in-house assays as no PCR
kits for helminth detection are commercially available. Hence,
cross-laboratory comparability is difﬁcult and the method is
restricted to a few reference laboratories. For a wider appli-
cation of PCR-based methods in developed countries, it would
be desirable to further stimulate combined testing of Schisto-
soma spp. with other helminths into stool-based multiplex PCR
assays [118].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
CMI Utzinger et al. New diagnostics for schistosomiasis 537Shortcomings of new diagnostic tests
Among the tests that are used for the diagnosis of schistoso-
miasis, only the urine ﬁltration, Kato–Katz, FLOTAC and Mini-
FLOTAC allow the quantiﬁcation of eggs in a given amount of
urine or stool, which provides information about the intensity of
infection and is a proxy for the number of worms harboured and
the morbidity experienced by the human host. The quantiﬁca-
tion of egg excretion also helps to assess the transmission po-
tential of populations living in endemic areas and guides
recommendations for the frequency of PCT interventions in the
frame of morbidity control initiatives [20]. Moreover, quantita-
tive diagnostic methods are used to determine the efﬁcacy of
praziquantel treatment in terms of egg reduction rates. The
colour intensity of POC-CCA tests, the amount of CAA
measured with the UCP-LF CAA and the amount of DNA
measured with PCR are reported to be correlated to the
number of eggs excreted and can give a certain estimate
regarding the intensity of infection [42,51,119]. In addition, both
CAA and CCA levels in serum and urine are reported to
correlate with worm numbers in experimental animals
[120,121]. However, a standardisation and clear indication is still
missing. It is widely assumed that antibodies remain detectable
after successful clearance of infection and that antibody tests are
therefore not applicable to assess treatment outcomes. Also,
DNA does not seem to clear for several months after prazi-
quantel administration; whether this is because of continuous
release of parasite DNA from eggs that are trapped in the host
or because of surviving adult worms remains to be determined
[105–107]. CAA and CCA are produced by living worms and
have been shown to clear within a few days or weeks after
successful treatment [55,58,122]. The POC-CCA and UCP-LF
CAA tests are therefore deemed suitable techniques for
assessing drug efﬁcacy in terms of cure rates.
A drawback for most diagnostic methods except stool mi-
croscopy and stool-based multiplex PCR assays is that only a
single pathogen species can be determined and that infections
with multiple intestinal parasites cannot be differentiated. Ideal
diagnostic approaches would allow the concurrent detection of
several pathogens in one biological sample (e.g. urine or stool).Outlook: new diagnostic tests in the next 5
yearsSchistosomiasis control programmes
As intensities and the prevalence of infection decrease in many
areas of the world, it will become more and more important for
schistosomiasis control and elimination programmes to adopt
the most sensitive (for detection of very light infection in-
tensities) and highly speciﬁc tests (to minimise the number ofClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyfalse-positive samples in areas approaching elimination of schis-
tosomiasis). In parasitological laboratories where microscopy is
readily available, it will be important to evaluate new techniques
such as Mini-FLOTAC in comparison to standard techniques
(Kato–Katz, FECT) under operational ﬁeld conditions to assess
their applicability and diagnostic accuracy in settings of light
infection intensity. However, microscopy alone—unless per-
formed on multiple samples— is unlikely to be sensitive enough
and will need to be supplemented by tests detecting antibodies,
antigen and/or DNA, particularly in areas where elimination of
schistosomiasis is the declared objective. The further develop-
ment of new RDTs holds promise to overcome shortcomings of
currently available rapid tests. At present, a urine-based RDT
able to detect CAA is anticipated for development and, once
commercialised, it might be used for rapid and exact mapping of
urogenital schistosomiasis. Serological tests may also play a role
to prove interruption of transmission and would be most suit-
able if available in an RDT format [123]. As shown by examples
from Japan and China, where schistosomiasis elimination has
been achieved or is in sight, respectively, elimination can only be
attained with a rigorous adaption of diagnostic tests to the
current stage of control, thereby reliably identifying also the last
transmission pockets [124,125].
Individual patient management
In peripheral healthcare centres, the use of POC-CCA and,
perhaps, additional RDTs could be highly beneﬁcial for
improved patient management. Indeed, the non-invasive test
procedure, the short turn-around time (results available within
less than 30 min) and the high sensitivity of the urine-based
POC-CCA may also attract interest in Western travel clinics
to employ this RDT as part of diagnostic algorithms.
PCR is available in reference laboratories in high-income
countries and its application for individual patient manage-
ment (e.g. in travel clinics) is likely to increase. If integrated into
commercially available multiplex PCR assays, the use of mo-
lecular helminth diagnostics may steadily rise across microbi-
ology laboratories in Europe, North America and elsewhere.
However, the technical limitations as well as the signiﬁcant
costs associated with the technical equipment, maintenance,
quality control and training of personnel will prevent its wider
application in most endemic areas of low- and middle-income
countries, at least for the foreseeable future.Concluding remarksAfter many years of general neglect, schistosomiasis and other
NTDs have come into sharper focus with real prospects for
escalating control and an ambitious roadmap towardsand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 529–542
FIG. 1. Different stages of a schistosomiasis control programme (from pre-control to post-elimination), highlighting stage-speciﬁc programmatic steps,
target and diagnostic test accuracy. (Note: the following grading system was used: +, low; ++, moderate; +++, high).
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diagnostics been acknowledged, particularly with regard to
diagnostic tools that are ﬁt for speciﬁc stages of a control pro-
gramme. In the current review, we highlight programmatic steps,
targets and diagnostic characteristics for the main stages of a
schistosomiasis control programme (Fig. 1), covering the entire
cycle from the pre-control stage (reconnaissance of the extent
of the programme, rapid mapping) to the post-elimination phase
(continued surveillance after veriﬁcation of transmission inter-
ruption). The current arsenal and characteristics of diagnostic
tools for schistosomiasis are summarised (Table 2) and allow
juxtaposing with the various stages of control. In view of growing
efforts to integrate the control and elimination of multiple
NTDs, there is a pressing need to develop, standardise and
validate novel diagnostic platforms that allow for mapping,
monitoring and surveillance of multiple NTDs. At the onset of
control, rapid, inexpensive, high throughput tools are required,
gradually replaced by POC assays and ﬁnally ultra-sensitive tools
that might be operated in reference laboratories. Clearly, elim-
ination can only be achieved if highly sensitive and speciﬁc
diagnostic techniques become available for people exposed to
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